Is retatrutide safe during pregnancy?

The short answer is no. Retatrutide (LY3437943) is an investigational triple receptor agonist that has not been approved by the FDA, the EMA, the MHRA, or any other national agency we track^[1]. There is no approved prescribing label to consult. Every Phase 2 and Phase 3 trial in the TRIUMPH programme excluded pregnant women, women who were breastfeeding, and women of childbearing potential who were not using adequate contraception^[2]. That means the question of whether retatrutide is safe during pregnancy cannot be answered by data, because no data exists.

If you are pregnant, planning a pregnancy, or breastfeeding and have questions about weight management or metabolic treatment, the right conversation is with your obstetrician or prescribing clinician. This article explains what the trial record shows, what the class-level evidence from approved medicines suggests, and why the absence of data here is itself meaningful.

Why retatrutide trials excluded pregnant women

Clinical trials for new medicines routinely exclude pregnant women during Phase 2 and Phase 3 development. Retatrutide is no exception. The Phase 2 obesity trial (NCT04881760), which enrolled 338 adults over 48 weeks and produced the published Jastreboff et al. results in the New England Journal of Medicine, required female participants to be neither pregnant nor breastfeeding, and to not intend to become pregnant^[2]. Women of childbearing potential had to use adequate contraception as defined by local regulatory standards. TRIUMPH-1, the Phase 3 obesity trial that completed primary endpoints in April 2026, followed the same exclusion structure^[3].

These exclusions are not arbitrary. They reflect two realities. First, Phase 3 trials aim to characterise efficacy and safety in a population where the outcome is attributable to the drug itself. Pregnancy introduces variables in pharmacokinetics, metabolism, and baseline maternal risk that would complicate interpretation. Second, and more importantly, animal reproductive toxicology data for the class has consistently raised concerns that make exposure during human pregnancy cautious territory.

What the GLP-1 class data suggests

Retatrutide is not approved and has no prescribing label, so there is no Section 8.1 pregnancy statement to quote directly. The closest analogy is the class: GLP-1, GIP, and glucagon receptor agonists. The approved dual agonist tirzepatide (Mounjaro) carries the following statement in its FDA-approved prescribing information: "there may be risks to the fetus from exposure to tirzepatide during pregnancy" based on animal study findings. In pregnant rats, fetal growth reductions and fetal abnormalities occurred at clinical exposure levels during organ development. In rabbits, reduced fetal growth was observed at clinically relevant doses^[4].

The pattern is consistent across the class. The Ozempic (semaglutide) prescribing information reports that in pregnant rats, the drug caused embryofetal mortality, structural abnormalities, and alterations to growth at clinically relevant exposures. Rabbit and primate studies showed early pregnancy losses and structural abnormalities. The label recommends discontinuing semaglutide at least two months before a planned pregnancy because of the long washout period^[5].

These findings do not mean that exposure causes harm in every case, or that the class is absolutely contraindicated in all contexts. They mean that the risk signal exists in animals, human data in pregnancy is insufficient to characterise the risk, and regulators have concluded the benefit-risk calculus during pregnancy is not favourable for weight-management use. Retatrutide, as a triple agonist adding the glucagon receptor arm, sits at least as far from a cleared safety profile as the approved single and dual agonists.

What about accidental exposure during pregnancy

Because retatrutide is not an approved medicine, an accidental exposure scenario would involve a grey-market or compound-pharmacy vial rather than a prescribed product. If you have taken any unlicensed or compounded product labelled as retatrutide and subsequently become pregnant, the most important step is to tell your obstetrician. There is no official pharmacovigilance registry for an unapproved compound, which means any such exposure is not being systematically tracked. Eli Lilly operates a formal pregnancy registry for its approved GLP-1 class products; no equivalent exists for investigational retatrutide. Your clinician may be able to document the exposure through a case report or an adverse event report to the relevant regulator in your country.

What we do not yet know

The entire reproductive safety profile of retatrutide in humans is an open question. There are no published human data on conception rates, miscarriage, or fetal outcomes in retatrutide-exposed pregnancies. The glucagon receptor agonism component of retatrutide is not shared by semaglutide or tirzepatide, and its specific reproductive pharmacology in humans has not been characterised. When and if retatrutide receives marketing authorisation, the label will include a pregnancy section based on accumulated animal data and any inadvertent human exposures tracked through trial monitoring; that label does not exist yet. The post-approval pharmacovigilance programmes of approved GLP-1 class drugs will build human evidence over years; retatrutide is behind that curve.

The bottom line

Retatrutide is investigational. No prescribing label exists. Every trial in the programme excluded pregnant women and women intending to become pregnant. The class-level evidence from approved GLP-1 agonists shows animal reproductive toxicity signals and leads regulators to recommend against use in pregnancy. Anyone who is pregnant, breastfeeding, or planning to become pregnant should not use retatrutide, and should discuss any questions about weight management or metabolic treatment with their obstetrician or a qualified clinician. For the regulatory status of retatrutide across the countries PeptideMethods tracks, see the retatrutide regulation pages.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.